磁共振成像技术在非酒精性脂肪性肝病肝脂肪定量中的应用

穆容; 陆伦根

doi:10.3969/j.issn.1001-5256.2020.06.038

磁共振成像技术在非酒精性脂肪性肝病肝脂肪定量中的应用

DOI: 10.3969/j.issn.1001-5256.2020.06.038

穆容,
陆伦根

上海交通大学医学院

基金项目:

中国肝炎防治基金会天晴肝病研究基金资助项目(TQGB20190182)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 996
- HTML全文浏览量: 53
- PDF下载量: 211
- 被引次数: 0
出版历程
- 收稿日期: 2019-11-18
- 出版日期: 2020-06-20

Advances in the application of magnetic resonance imaging in hepatic fat quantification in patients with nonalcoholic fatty liver disease

Mu Rong,
Lu LunGen

Shanghai Jiao Tong University School of Medicine

Research funding:

摘要

摘要:
肝脂肪含量是非酒精性脂肪性肝病的早期诊断、疾病分级和疗效评估的重要指标。多种磁共振技术已被用来评估肝脂肪含量,其中磁共振波谱分析和化学位移编码成像获得的质子密度脂肪分数已能精确定量肝脏脂肪,被认为是脂肪肝诊断的影像学金标准并被应用于临床研究中。回顾定量检测肝脂肪含量的磁共振技术的研究进展,以期为临床应用和实验研究提供参考。
- 非酒精性脂肪性肝病 /
- 磁共振成像 /
- 脂肪定量
Abstract:
Hepatic fat content is an important index for the early diagnosis,disease grading,and outcome evaluation of nonalcoholic fatty liver disease( NAFLD). Various magnetic resonance imaging( MRI) methods have been used to determine hepatic fat content in NAFLD,among which proton density fat fraction obtained by magnetic resonance spectroscopy and chemical-shift-encoded MRI can achieve precise quantification of hepatic fat and therefore,it is considered the imaging gold standard for the diagnosis of fatty liver disease and has been applied in clinical research. This article reviews the research advances in the MRI techniques for quantification of hepatic fat content,in order to provide a reference for clinical application and experiment.
- nonalcoholic fatty liver disease /
- magnetic resonance imaging /
- fat quantification

HTML全文

参考文献(35)

[1] DIEHL AM,DAY C. Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med,2017,377(21):2063-2073.

[2] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.

[3] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[4] HOUGHTON D,ZALEWSKI P,HALLSWORTH K,et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function[J]. J Hepatol,2019,70(6):1203-1213.

[5] KARLAS T,PETROFF D,SASSO M,et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis[J]. J Hepatol,2017,66(5):1022-1030.

[6] European Association for the Study of the Liver(EASI),European Association for the Study of Diabetes(EASD),European Association for the Study of Obesity(EASO). EASL-EASDEASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.

[7] COTLER SJ,GUZMAN G,LAYDEN-ALMER J,et al. Measurement of liver fat content using selective saturation at 3. 0 T[J]. J Magn Reson Imaging,2007,25(4):743-748.

[8] MENG XY,LI ZY,LI H. Magnetic resonance imaging in evaluating fat content quantitatively:A review[J]. J Chin Clin Med Imaging,2018,29(5):362-365.(in Chinese)孟祥玉，李子英，李慧．磁共振成像技术量化评估脂肪含量的研究进展[J]．中国临床医学影像杂志，2018,29(5):362-365.

[9] CHENG WH,SOUDABEH FD,JONATHAN CH,et al. Fat Quantification in the Abdomen[J]. Top Magn Reson Imaging,2017,26(6):221-227.

[10] JOY TR,MCKENZIE CA,TIRONA RG,et al. Sitagliptin in patients with non-alcoholic steatohepatitis:A randomized,placebo-controlled trial[J]. World J Gastroenterol,2017,23(1):141-150.

[11] LEVIN YS,YOKOO T,WOLFSON T,et al. Effect of echosampling strategy on the accuracy of out-of-phase and inphase multiecho gradient-echo MRI hepatic fat fraction estimation[J]. J Magn Reson Imaging,2014,39(3):567-575.

[12] PARK CC,NGUYEN P,HERNANDEZ C,et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology,2017,152(3):598-607.

[13] YOKOO T,SERAI SD,PIRASTEH A,et al. Linearity,bias,and precision of hepatic proton density fat fraction measurements by using MR imaging:A meta-analysis[J]. Radiology,2018,286(2):486-498.

[14] NOUREDDIN M,LAM J,PETERSON MR,et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials[J].Hepatology,2013,58(6):1930-1940.

[15] CAUSSY C,REEDER SB,SIRLIN CB,et al. Noninvasive,quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology,2018,68(2):763-772.

[16] PATEL J,BETTENCOURT R,CUI J,et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis[J]. Therap Adv Gastroenterol,2016,9(5):692-701.

[17] AJMERA V,PARK CC,CAUSSY C,et al. Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2018,155(2):307-310.

[18] KANG BK,KIM M,SONG SY,et al. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders:Validation with MRS and histology[J]. Br J Radiol,2018,91(1089):20170378.

[19] HUI SCN,SO HK,CHAN DFY,et al. Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease[J]. Eur J Radiol,2018,107:7-13.

[20] FAZELI DEHKORDY S,FOWLER KJ,MAMIDIPALLI A,et al.Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes[J].Eur Radiol,2019,29(5):2474-2480.

[21] LV S,JIANG S,LIU S,et al. Noninvasive quantitative detection methods of liver fat content in nonalcoholic fatty liver disease[J]. J Clin Transl Hepatol,2018,6(2):217-221.

[22] JANG JK,LEE SS,KIM B,et al. Agreement and reproducibility of proton density fat fraction measurements using commercial MR sequences across different platforms:A multivendor,multi-institutional phantom experiment[J]. Invest Radiol,2019,54(8):517-523.

[23] STERN C,CASTERA L. Non-invasive diagnosis of hepatic steatosis[J]. Hepatol Int,2017,11(1):70-78.

[24] HUIJBERS A,WANTEN G,DEKKER HM,et al. Noninvasive quantitative assessment of hepatic steatosis by proton magnetic resonance spectroscopy among adult patients receiving home parenteral nutrition[J]. JPEN J Parenter Enteral Nutr,2018,42(4):778-785.

[25] DULAI PS,SIRLIN CB,LOOMBA R. MRI and MRE for noninvasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH:Clinical trials to clinical practice[J].J Hepatol,2016,65(5):1006-1016.

[26] LEE DH. Imaging evaluation of non-alcoholic fatty liver disease:Focused on quantification[J]. Clin Mol Hepatol,2017,23(4):290-301.

[27] RUNGE JH,SMITS LP,VERHEIJ J,et al. MR spectroscopyderived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis[J]. Radiology,2018,286(2):547-556.

[28] CAO Q,XU S,LI S,et al. Quantification of hepatic lipid using7. 0T proton magnetic resonance spectroscopy and computed tomography in mild alcoholic steatotic mice[J]. J Liver,2018,7(4):234.

[29] SHENOY-BHANGLE A,BALIYAN V,KORDBACHEH H,et al. Diffusion weighted magnetic resonance imaging of liver:Principles,clinical applications and recent updates[J]. World J Hepatol,2017,9(26):1081-1091.

[30] GUIU B,PETIT JM,CAPITAN V,et al. Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver:A 3. 0-T MR study[J]. Radiology,2012,265(1):96-103.

[31] LEE Y,KIM H. Assessment of diffusion tensor MR imaging(DTI)in liver fibrosis with minimal confounding effect of hepatic steatosis[J]. Magn Reson Med,2015,73(4):1602-1608.

[32] LI C,YE J,PENG Y,et al. Evaluation of diffusion kurtosis imaging in stratification of nonalcoholic fatty liver disease and early diagnosis of nonalcoholic steatohepatitis in a rabbit model[J].Magn Reson Imaging,2019,63:267-273.

[33] JOO I,LEE JM,YOON JH,et al. Nonalcoholic fatty liver disease:Intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model[J]. Radiology,2013:122506.

[34] MURPHY P,HOOKER J,ANG B,et al. Associations between histologic features of nonalcoholic fatty liver disease(NAFLD)and quantitative diffusion-weighted MRI measurements in adults[J]. J Magn Reson Imaging,2015,41(6):1629-1638.

[35] SHIN HJ,YOON H,KIM MJ,et al. Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children[J]. World J Gastroenterol,2018,24(27):3013-3020.

施引文献

资源附件(0)

访问统计